Summary by Moomoo AI
BioVie has issued a supplement to its prospectus, effectively suspending the continuous offering of its Class A common stock under a previously established Sales Agreement with Cantor Fitzgerald & Co. as of September 25, 2024. The supplement amends information from the original prospectus supplement dated January 19, 2024, and the prospectus dated August 28, 2023. Since the initial offering, BioVie has sold $6,446 worth of shares. The company's common stock, which is traded on the Nasdaq under the symbol BIVI, had a last reported sale price of $1.18 per share on September 24, 2024. The Sales Agreement remains effective, but no further sales will occur until a new prospectus supplement is filed with the Securities and Exchange Commission.